RxDoctor Payments Data

Katherine Ochsner, MD

Ophthalmology · Wilmington, NCNPI 1104917657

Payments from drug & device makers

$14,633in general payments, 2019–2025

Across 116 payments — averaging $126.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$8K
  • Ivantis, Inc$4K
  • AbbVie$717
  • Bausch & Lomb Americas Inc.$467
  • Alcon$388
  • NEW World Medical,inc.$359
  • plus $391 from 11 others

What the payments were for

  • Food & beverage$2,28898%
  • Gifts$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,633 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$440,804
Medicare patients
826
Services billed
3,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost222$110,226
RestasisCyclosporine65$73,605
RocklatanNetarsudil Mesylat/Latanoprost172$71,163
CombiganBrimonidine Tartrate/Timolol146$64,243
VyzultaLatanoprostene Bunod173$60,377
SimbrinzaBrinzolamide/Brimonidine Tart181$55,244
RhopressaNetarsudil Mesylate106$43,807
Alphagan PBrimonidine Tartrate85$30,083
Brinzolamide115$29,688
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol110$20,025
Brimonidine Tartrate427$17,842
MieboPerfluorohexyloctane/Pf23$17,135
AzoptBrinzolamide30$14,727
Prednisolone Acetate211$13,788
Dorzolamide-TimololDorzolamide/Timolol/Pf71$12,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$717$278,158518 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$55$114,970278 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo, Xiidra$467$90,041214 claims
AlconSimbrinza, Azopt$388$69,970211 claims
Akorn, Inc.Zioptan$11$12,68137 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate$40$12,25047 claims
Thea Pharma Inc.Iyuzeh$32$8,84930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →